XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
EPS Calculation (Tables)
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of reconciliation of the earnings and shares used in calculating basic and diluted EPS
The following table presents a reconciliation of the earnings/(loss) and shares used in calculating basic and diluted earnings/(loss) per share for the three and nine months ended September 30, 2021 and 2020:
 
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In Thousands, Except Per Share Amounts)2021202020212020
Basic Earnings/(Loss) per Share:
Net income/(loss) to common stockholders$132,511 $87,210 $284,747 $(725,207)
Dividends declared on preferred stock(8,218)(8,219)(24,656)(21,578)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities(435)(325)(915)(91)
Net income/(loss) to common stockholders - basic$123,858 $78,666 $259,176 $(746,876)
Basic weighted average common shares outstanding440,889 453,323 444,481 453,170 
Basic Earnings/(Loss) per Share$0.28 $0.17 $0.58 $(1.65)
Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic$123,858 $78,666 $259,176 $(746,876)
Interest expense on Convertible Senior Notes 3,920 3,898 11,743 — 
Dividends, dividend equivalents and undistributed earnings allocated to participating securities435 — 915 — 
Net income/(loss) to common stockholders - diluted$128,213 $82,564 $271,834 $(746,876)
Basic weighted average common shares outstanding440,889 453,323 444,481 453,170 
Effect of assumed conversion of Convertible Senior Notes to common shares28,920 28,920 28,920 — 
Unvested and vested restricted stock units3,377 — 1,623 — 
Effect of Warrants— 11,297 — — 
Diluted weighted average common shares outstanding (1)
473,186 493,540 475,024 453,170 
Diluted Earnings/(Loss) per Share$0.27 $0.17 $0.57 $(1.65)
(1)At September 30, 2021, the Company had approximately 7.0 million equity instruments outstanding that were included in the calculation of diluted EPS for the three and nine months ended September 30, 2021.  These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $4.21. These equity instruments may continue to have a dilutive impact on future EPS.